231 related articles for article (PubMed ID: 35156645)
1. Predictive and Prognostic Value of Tumor- Infiltrating Lymphocytes for Pathological Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
Mohammed AA; Mostafa Elsayed F; Algazar M; Rashed HE
Gulf J Oncolog; 2022 Jan; 1(38):53-60. PubMed ID: 35156645
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
Li X; Tan Q; Li H; Yang X
J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
[TBL] [Abstract][Full Text] [Related]
3. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
6. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
[TBL] [Abstract][Full Text] [Related]
8. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers.
Ruan M; Tian T; Rao J; Xu X; Yu B; Yang W; Shui R
Diagn Pathol; 2018 Aug; 13(1):66. PubMed ID: 30170605
[TBL] [Abstract][Full Text] [Related]
11. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
13. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
Pang J; Wang S; Liao L; Liu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
[TBL] [Abstract][Full Text] [Related]
14. Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes in Patients with Advanced Breast Cancer Treated with Primary Systemic Therapy.
Agarwal G; Vishvak Chanthar KMM; Katiyar S; Kumari N; Krishnani N; Sabaretnam M; Chand G; Mishra A; Lal P
World J Surg; 2023 May; 47(5):1238-1246. PubMed ID: 36735048
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer.
Zhang L; Wang XI; Zhang S
Hum Pathol; 2018 Oct; 80():47-54. PubMed ID: 29883779
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Infiltrating Lymphocytes/Plasmocytes in Chemotherapeutically Non-Influenced Triple-Negative Breast Cancers - Correlation with Morphological and Clinico-Pathological Parameters.
Kolečková M; Kolář Z; Ehrmann J; Kořínková G; Zlámalová N; Melichar B; Trojanec R
Klin Onkol; 2019; 32(5):380-387. PubMed ID: 31610672
[TBL] [Abstract][Full Text] [Related]
20. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.
Pruneri G; Vingiani A; Bagnardi V; Rotmensz N; De Rose A; Palazzo A; Colleoni AM; Goldhirsch A; Viale G
Ann Oncol; 2016 Feb; 27(2):249-56. PubMed ID: 26598540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
